ArticleExperimental and therapeutic medicine2017
Anthelmintic drug albendazole arrests human gastric cancer cells at the mitotic phase and induces apoptosis.
Article in Experimental and therapeutic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cellsOncology reports · 2026Article
- Transcriptome analysis reveals the anticancer effects of fenbendazole on ovarian cancer: an in vitro and in vivo study.BMC cancer · 2024Article
- Review
- Improving the Solubility, Stability, and Bioavailability of Albendazole through Synthetic Salts.Molecules (Basel, Switzerland) · 2024Article
- Combinations of the azaquinazoline anti-Frontiers in microbiology · 2024Article
- ID-Checker Technology for the Highly Selective Macroscale Delivery of Anticancer Agents to the Cancer Cells.Journal of medicinal chemistry · 2022Article
- Identification of antiparasitic drug targets using a multi-omics workflow in the acanthocephalan model.BMC genomics · 2022Article
- Review
- Treatment of breast and colon cancer cell lines with anti-helmintic benzimidazoles mebendazole or albendazole results in selective apoptotic cell death.Journal of cancer research and clinical oncology · 2021Article
- Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update.The Korean journal of parasitology · 2021Review
- Albendazole exerts antiproliferative effects on prostate cancer cells by inducing reactive oxygen species generation.Oncology letters · 2021Article
- Repositioning of Antiparasitic Drugs for Tumor Treatment.Frontiers in oncology · 2021Review
- The Widely Used Antihelmintic Drug Albendazole is a Potent Inducer of Loss of Heterozygosity.Frontiers in pharmacology · 2021Article
- Article
- Solid Polymeric Nanoparticles of Albendazole: Synthesis, Physico-Chemical Characterization and Biological Activity.Molecules (Basel, Switzerland) · 2020Article
- The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs.Immune network · 2020Review
- Repositioning Flubendazole for Spinal Cord Injury.Journal of neurotrauma · 2019Article
- Antitumor Effect of Albendazole on Cutaneous Squamous Cell Carcinoma (SCC) Cells.BioMed research international · 2019Article
- Solid Lipid Nanoparticles of Albendazole for Enhancing Cellular Uptake and Cytotoxicity against U-87 MG Glioma Cell Lines.Molecules (Basel, Switzerland) · 2017Article
Corrections and comments
- Retraction · 2024-03-26Concerns/Issues about Data · Duplication of/in Image · Euphemisms for Duplication · Investigation by Journal/Publisher · Unreliable Data · · See also: https://pubpeer.com/publications/41AB9A6A9D6B1894B382E868E0BA21
- Retracted
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As microtubules have a vital function in the cell cycle, oncologists have developed microtubule inhibitors capable of preventing uncontrolled cell division, as in the case of cancer. The anthelmintic drug albendazole (ABZ) has been demonstrated to inhibit hepatocellular, ovarian and prostate cancer cells via microtubule targeting. However, its activity against human gastric cancer (GC) cells has remained to be determined. In the present study, ABZ was used to treat GC cells (MKN-45, SGC-7901 and MKN-28). A a CCK-8 cell proliferation assay was performed to assess the effects of ABZ on cell viability and cell cycle changes were assessed using flow cytometry. SGC-7901 cells were selected for further study, and flow cytometry was employed to determine the apoptotic rate, immunofluorescence analysis was employed to show changes of the microtubule structure as well as the subcellular localization and expression levels of cyclin B1, and western blot analysis was used to identify the dynamics of microtubule assembly. The expression levels of relevant proteins, including cyclin B1 and Cdc2, the two subunits of mitosis-promoting factor as well as apoptosis-asociated proteins were also assessed by western blot analysis. The results showed that ABZ exerted its anti-cancer activity in GC cell lines by disrupting microtubule formation and function to cause mitotic arrest, which is also associated with the accumulation of cyclin B1, and consequently induces apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.